Indolent Lymphoma - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 13 PAGES: 156

Indolent Lymphoma - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Indolent Lymphoma - Pipeline Review, H2 2011', provides an overview of the Indolent Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. 'Indolent Lymphoma - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Indolent Lymphoma.
- A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Indolent Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effectiv

More Info
									Indolent Lymphoma – Pipeline Review, H2 2011




             Indolent Lymphoma - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1233IDB

                                                                                          Publication Date: August 2011




Indolent Lymphoma – Pipeline Review, H2 2011                                                                      GMDHC1233IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                         Page(1)
Indolent Lymphoma – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                   2
List of Tables                                                                                                      9
List of Figures                                                                                                    10
Introduction                                                                                                       11
     Global Markets Direct Report Coverage                                                                         11
Indolent Lymphoma Overview                                                                                         12
Therapeutics Development                                                                                           13
     An Overview of Pipeline Products for Indolent Lymphoma                                                        13
Indolent Lymphoma Therapeutics under Development by Companies                                                      15
Indolent Lymphoma Therapeutics under Investigation by Universities/Institutes                                      17
Late Stage Products                                                                                                20
     Comparative Analysis                                                                                          20
Mid Clinical Stage Products                                                                                        21
     Comparative Analysis                                                                                          21
Early Clinical Stage Products                                                                                      22
     Comparative Analysis                                                                                          22
Indolent Lymphoma Therapeutics - Products under Development by Companies                                           23
Indolent Lymphoma Therapeutics - Products under Investigation by Universities/Institutes                           25
Companies Involved in Indolent Lymphoma Therapeutics Development                                                   28
     F. Hoffmann-La Roche Ltd.                                                                                     28
     Abbott Laboratories                                                                                           28
     GlaxoSmithKline plc                                                                                           29
     MMR Information Systems, Inc.                                                                                 29
     Gilead Sciences, Inc.                                                                                         30
     Merck & Co., Inc.                                                                                             30
     Cephalon, Inc.                                                                                                31
     Pfizer Inc.                                                                                                   31
     Cell Therapeutics, Inc.                                                                                       32
     Celgene Corporation                                                                                           32
     Accentia Biopharmaceuticals, Inc.                                                                             33
     Mundipharma International Limited                                                                             33
     SymBio Pharmaceuticals Limited                                                                                34
     Kantonsspital Aarau AG                                                                                        34
     Pharmascience Inc.                                                                                            34
     S*BIO Pte Ltd                                                                                                 35
Indolent Lymphoma - Therapeutics Assessment                                                                        36
     Assessment by Monotherapy Products                                                                            36
     Assessment by Combination Products                                                                            37
     Assessment by Route of Administration                                                                         38
     Assessment by Molecule Type                                                                                   40
Drug Profiles                                                                                                      42
     RG7159 - Drug Profile                                                                                         42
          Product Description                                                                                      42
          Mechanism of Action                                                                                      42
          R&D Progress                                                                                             42
     MAbThera - Drug Profile                                                                                       43
          Product Description                                                                                      43


Indolent Lymphoma – Pipeline Review, H2 2011                                               GMDHC1233IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(2)
Indolent Lymphoma – Pipeline Review, H2 2011


          Mechanism of Action                                                                                     43
          R&D Progress                                                                                            43
     SB-1518 - Drug Profile                                                                                       45
          Product Description                                                                                     45
          Mechanism of Action                                                                                     45
          R&D Progress                                                                                            45
     BiovaxID - Drug Profile                                                                                      47
          Product Description                                                                                     47
          Mechanism of Action                                                                                     47
          R&D Progress                                                                                            47
     SyB L-0501 - Drug Profile                                                                                    48
          Product Description                                                                                     48
          Mechanism of Action                                                                                     48
          R&D Progress                                                                                            48
     GS 1101 - Drug Profile                                                                                       49
          Product Description                                                                                     49
          Mechanism of Action                                                                                     49
          R&D Progress                                                                                            49
     AEG35156 - Drug Profile                                                                                      50
          Product Description                                                                                     50
          Mechanism of Action                                                                                     50
          R&D Progress                                                                                            50
     Rituximab + Gemcitabine + Oxaliplatin - Drug Profile                                                         51
          Product Description                                                                                     51
          Mechanism of Action                                                                                     51
          R&D Progress                                                                                            51
     Rituxan + BEAM + Autologous Stem Cell Transplantation - Drug Profile                                         52
          Product Description                                                                                     52
          Mechanism of Action                                                                                     52
          R&D Progress                                                                                            52
     Velcade + Alvocidib - Drug Profile                                                                           53
          Product Description                                                                                     53
          Mechanism of Action                                                                                     53
          R&D Progress                                                                                            53
     Bendamustine + Bortezomib - Drug Profile                                                                     54
          Product Description                                                                                     54
          Mechanism of Action                                                                                     54
          R&D Progress                                                                                            54
     Flavopiridol + Fludarabine + Rituximab - Drug Profile                                                        56
          Product Description                                                                                     56
          Mechanism of Action                                                                                     56
          R&D Progress                                                                                            56
     VR-CHOP - Drug Profile                                                                                       57
          Product Description                                                                                     57
          Mechanism of Action                                                                                     57
          R&D Progress                                                                                            58
     Everolimus + Bortezomib - Drug Profile                                                                       59
          Product Description                                                                                     59




Indolent Lymphoma – Pipeline Review, H2 2011                                              GMDHC1233IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(3)
Indolent Lymphoma – Pipeline Review, H2 2011


          Mechanism of Action                                                                                     59
          R&D Progress                                                                                            59
     Rituximab - Drug Profile                                                                                     61
          Product Description                                                                                     61
          Mechanism of Action                                                                                     61
          R&D Progress                                                                                            61
     Velcade + Rituximab - Drug Profile                                                                           62
          Product Description                                                                                     62
          Mechanism of Action                                                                                     62
          R&D Progress                                                                                            62
     Rituximab + Dexamethasone - Drug Profile                                                                     63
          Product Description                                                                                     63
          Mechanism of Action                                                                                     63
          R&D Progress                                                                                            63
     Vorinostat - Drug Profile                                                                                    65
          Product Description                                                                                     65
          Mechanism of Action                                                                                     65
          R&D Progress                                                                                            65
     Pentostatin + Cyclophosphamide + Rituximab - Drug Profile                                                    66
          Product Description                                                                                     66
          Mechanism of Action                                                                                     66
          R&D Progress                                                                                            66
     Rituximab + Cyclophosphamide - Drug Profile                                                                  68
          Product Description                                                                                     68
          Mechanism of Action                                                                                     68
          R&D Progress                                                                                            68
     Zolinza - Drug Profile                                                                                       70
          Product Description                                                                                     70
          Mechanism of Action                                                                                     70
          R&D Progress                                                                                            70
     CMC-544 - Drug Profile                                                                                       72
          Product Description                                                                                     72
          Mechanism of Action                                                                                     72
          R&D Progress                                                                                            72
     SDX-105 + Rituxan - Drug Profile                                                                             73
          Product Description                                                                                     73
          Mechanism of Action                                                                                     73
          R&D Progress                                                                                            73
     GS 1101 + Bendamustine + Rituximab - Drug Profile                                                            74
          Product Description                                                                                     74
          Mechanism of Action                                                                                     74
          R&D Progress                                                                                            74
     GS 1101 + Bendamustine - Drug Profile                                                                        76
          Product Description                                                                                     76
          Mechanism of Action                                                                                     76
          R&D Progress                                                                                            76
     GS 1101 + Rituxan - Drug Profile                                                                             77
          Product Description                                                                                     77




Indolent Lymphoma – Pipeline Review, H2 2011                                              GMDHC1233IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(4)
Indolent Lymphoma – Pipeline Review, H2 2011


          Mechanism of Action                                                                                     77
          R&D Progress                                                                                            77
     PRO131921 - Drug Profile                                                                                     79
          Product Description                                                                                     79
          Mechanism of Action                                                                                     79
          R&D Progress                                                                                            79
     R05072759 + Bendamustine - Drug Profile                                                                      80
          Product Description                                                                                     80
          Mechanism of Action                                                                                     80
          R&D Progress                                                                                            80
     Arzerra + Bendamustine - Drug Profile                                                                        81
          Product Description                                                                                     81
          Mechanism of Action                                                                                     81
          R&D Progress                                                                                            81
     Pixantrone + Rituximab + Fludarabine - Drug Profile                                                          83
          Product Description                                                                                     83
          Mechanism of Action                                                                                     83
          R&D Progress                                                                                            83
     BBR 2778 + Fludarabine + Dexamethasone + Rituximab - Drug Profile                                            85
          Product Description                                                                                     85
          Mechanism of Action                                                                                     85
          R&D Progress                                                                                            85
     Zevalin + Rituximab - Drug Profile                                                                           87
          Product Description                                                                                     87
          Mechanism of Action                                                                                     87
          R&D Progress                                                                                            87
     Dolastatin 10 - Drug Profile                                                                                 88
          Product Description                                                                                     88
          Mechanism of Action                                                                                     88
          R&D Progress                                                                                            88
     Rituximab + Dexamethasone - Drug Profile                                                                     89
          Product Description                                                                                     89
          Mechanism of Action                                                                                     89
          R&D Progress                                                                                            89
     RO5072759 + Bendamustine - Drug Profile                                                                      90
          Product Description                                                                                     90
          Mechanism of Action                                                                                     90
          R&D Progress                                                                                            90
     Rituximab - Drug Profile                                                                                     91
          Product Description                                                                                     91
          Mechanism of Action                                                                                     91
          R&D Progress                                                                                            91
     Velcade + BEAM + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile                           92
          Product Description                                                                                     92
          Mechanism of Action                                                                                     92
          R&D Progress                                                                                            93
     Vorinostat + Rituximab - Drug Profile                                                                        94
          Product Description                                                                                     94




Indolent Lymphoma – Pipeline Review, H2 2011                                              GMDHC1233IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(5)
Indolent Lymphoma – Pipeline Review, H2 2011


          Mechanism of Action                                                                                                        94
          R&D Progress                                                                                                               94
     506U78 - Drug Profile                                                                                                           95
          Product Description                                                                                                        95
          Mechanism of Action                                                                                                        95
          R&D Progress                                                                                                               95
     Bortezomib + Bendamustine + Rituximab - Drug Profile                                                                            96
          Product Description                                                                                                        96
          Mechanism of Action                                                                                                        96
          R&D Progress                                                                                                               96
     Proleukin + Cyclophosphamide + Therapeutic Autologous Lymphocytes - Drug Profile                                                97
          Product Description                                                                                                        97
          Mechanism of Action                                                                                                        97
          R&D Progress                                                                                                               98
     Tumor Derived Immunoglobulin Idiotype With Keyhole Limpet Hemocyanin Conjugate Vaccine + Sargramostim + Cyclophosphamide +
     Vincristine + Prednisone + Doxorubicin - Drug Profile                                                                           99
          Product Description                                                                                                        99
          Mechanism of Action                                                                                                        99
          R&D Progress                                                                                                               100
     Treanda + Ofatumumab - Drug Profile                                                                                             101
          Product Description                                                                                                        101
          Mechanism of Action                                                                                                        101
          R&D Progress                                                                                                               101
     Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile                                                                    102
          Product Description                                                                                                        102
          Mechanism of Action                                                                                                        102
          R&D Progress                                                                                                               102
     Rituximab + THP-COP - Drug Profile                                                                                              104
          Product Description                                                                                                        104
          Mechanism of Action                                                                                                        104
          R&D Progress                                                                                                               104
     Rituxan + FavId + GM-CSF - Drug Profile                                                                                         106
          Product Description                                                                                                        106
          Mechanism of Action                                                                                                        106
          R&D Progress                                                                                                               106
     Rituximab + Velcade + Cladribine - Drug Profile                                                                                 107
          Product Description                                                                                                        107
          Mechanism of Action                                                                                                        107
          R&D Progress                                                                                                               108
     Rituximab + Bortezomib + Cyclophosphamide + Prednisone - Drug Profile                                                           109
          Product Description                                                                                                        109
          Mechanism of Action                                                                                                        109
          R&D Progress                                                                                                               110
     Rituximab + Cyclophosphamide + Fludarabine + Mesna + Sirolimus + Radiation theraphy + Stemcell transplantation - Drug Profile   111
          Product Description                                                                                                        111
          Mechanism of Action                                                                                                        112
          R&D Progress                                                                                                               113
     Rituximab + Zevalin + Cyclophosphamide + Fludarabine + Allogeneic Stem Cell Transplantation - Drug Profile                      114
          Product Description                                                                                                        114


Indolent Lymphoma – Pipeline Review, H2 2011                                                            GMDHC1233IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                              Page(6)
Indolent Lymphoma – Pipeline Review, H2 2011


          Mechanism of Action                                                                                                       114
          R&D Progress                                                                                                              115
     Alemtuzumab + Donor Lymphocytes + Cyclosporine + Fludarabine + Melphalan + Stem Cell Transplantation - Drug Profile            116
          Product Description                                                                                                       116
          Mechanism of Action                                                                                                       116
          R&D Progress                                                                                                              117
     Recombinnat Interferon alfa + Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Vincristine sulfate - Drug Profile   118
          Product Description                                                                                                       118
          Mechanism of Action                                                                                                       118
          R&D Progress                                                                                                              118
     Rituximab + Bortezomib + Fludarabine - Drug Profile                                                                            120
          Product Description                                                                                                       120
          Mechanism of Action                                                                                                       120
          R&D Progress                                                                                                              120
     Rituximab + yttrium Y 90 ibritumomab tiuxetan - Drug Profile                                                                   122
          Product Description                                                                                                       122
          Mechanism of Action                                                                                                       122
          R&D Progress                                                                                                              122
     Proleukin + Therapeutic Autologous Lymphocytes + Cyclophosphamide + Prednisone + Vincristine Sulfate - Drug Profile            123
          Product Description                                                                                                       123
          Mechanism of Action                                                                                                       123
          R&D Progress                                                                                                              124
     Rituximab + Lenalidomide - Drug Profile                                                                                        125
          Product Description                                                                                                       125
          Mechanism of Action                                                                                                       125
          R&D Progress                                                                                                              125
     Rituximab + Bendamustine + Obatoclax - Drug Profile                                                                            127
          Product Description                                                                                                       127
          Mechanism of Action                                                                                                       127
          R&D Progress                                                                                                              127
     Rituximab + Bendamustine - Drug Profile                                                                                        129
          Product Description                                                                                                       129
          Mechanism of Action                                                                                                       129
          R&D Progress                                                                                                              129
     Ofatumumab - Drug Profile                                                                                                      130
          Product Description                                                                                                       130
          Mechanism of Action                                                                                                       130
          R&D Progress                                                                                                              130
     Bendamustine - Drug Profile                                                                                                    131
          Product Description                                                                                                       131
          Mechanism of Action                                                                                                       131
          R&D Progress    
								
To top